Skip to content
Study details
Enrolling now

Propranolol Trial for Aggression and Self-Injury in People with Autism

Jeremy Veenstra-vanderweele
NCT IDNCT07091279ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

60

Study length

about 3.1 years

Ages

12–40

Locations

2 sites in NY

What this study is about

This trial is testing if propranolol can help reduce aggression, self-injury, and severe disruptive behaviors in people with autism. Participants will receive either propranolol or a placebo daily for 12 weeks. After the initial period, some participants may continue receiving propranolol for another 12 weeks.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take Propranolol

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

propranolol (Non-selective beta blocker; slows heart rate)

Endpoints

Primary: Incidence of safety concerns and side effects associated with high-dose propranolol, including changes in blood pressure, pulse, and occurrence of dysrhythmias.

Body systems

Psychiatry / Mental Health